Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Bought by Farther Finance Advisors LLC

Farther Finance Advisors LLC increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 226.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 758 shares of the medical equipment provider’s stock after buying an additional 526 shares during the quarter. Farther Finance Advisors LLC’s holdings in Lantheus were worth $83,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of LNTH. Measured Wealth Private Client Group LLC acquired a new position in Lantheus in the 3rd quarter worth $272,000. New York State Teachers Retirement System lifted its stake in shares of Lantheus by 3.3% in the third quarter. New York State Teachers Retirement System now owns 91,568 shares of the medical equipment provider’s stock worth $10,050,000 after acquiring an additional 2,902 shares in the last quarter. abrdn plc purchased a new position in Lantheus in the third quarter valued at about $662,000. Smith Group Asset Management LLC grew its stake in Lantheus by 24.2% during the 3rd quarter. Smith Group Asset Management LLC now owns 6,023 shares of the medical equipment provider’s stock valued at $661,000 after purchasing an additional 1,172 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in Lantheus by 17.7% during the 3rd quarter. Nisa Investment Advisors LLC now owns 7,819 shares of the medical equipment provider’s stock worth $858,000 after purchasing an additional 1,176 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Stock Up 1.3 %

Shares of LNTH stock opened at $85.15 on Wednesday. The business has a 50 day moving average of $106.48 and a two-hundred day moving average of $96.39. The company has a market cap of $5.92 billion, a P/E ratio of 14.17 and a beta of 0.51. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on LNTH shares. StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Friday, November 8th. JMP Securities dropped their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday, November 7th. B. Riley increased their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Truist Financial reissued a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, Redburn Atlantic started coverage on Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $122.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.